<p><strong>Adults including elderly</strong>: The recommended starting dose is Mirabegron 25 mg tablet once daily with or without food. Based on individual patient efficacy and tolerability the dose may be increased to Mirabegron 50 mg tablet once daily.<br />
<br />
<strong>Renal or hepatic impairment</strong>:</p>

<ul>
	<li>Patients with severe renal impairment (ClCr 15 to 29 mL/min or eGFR 15 to 29 mL/min/1.73 m2) or moderate hepatic impairment (Child-Pugh Class B), the daily dose of Mirabegron should not exceed 25 mg tablet once daily.</li>
	<li>Mirabegron has not been studied in patients with end stage renal disease (GFR &lt;15 mL/min/1.73 m2 or patients requiring haemodialysis) or severe hepatic impairment (Child Pugh Class C) and it is therefore not recommended for use in these patient populations.</li>
</ul>

<p><strong>Gender</strong>: No dose adjustment is necessary according to gender.<br />
<br />
<strong>Paediatric population</strong>: The safety and efficacy of Mirabegron in children below 18 years of age have not yet been established.</p>

<p>&nbsp;</p>

<p><strong>Administration</strong></p>

<p>Mirabegron tablet is to be taken once daily, with liquids, swallowed whole and is not to be chewed, divided, or crushed.</p>